Savara Inc Preferred Stock, Par or Stated Value Per Share
Savara Inc (SVRA) had Preferred Stock, Par or Stated Value Per Share of $0.00 per share as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockParOrStatedValuePerShare · last filed 2026-03-13
- 2025-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2024-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2023-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2022-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
| Period end | Preferred Stock, Par or Stated Value Per Share |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-13 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-07 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-30 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-10 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-13 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-07 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-14 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-06 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-14 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-24 |
| 2013-12-31 | $0.00 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |